Age-related macular degeneration, often abbreviated as AMD, is one of the leading causes of vision loss among older adults worldwide. In Asia, where populations are ageing rapidly, its impact is particularly profound. For many, the disease quietly erodes central vision, making everyday activities such as reading, driving, and recognising faces increasingly difficult. Against this backdrop, the Translational Asian Age-related Macular Degeneration Programme, or TAAP for short, has emerged as a bold and ambitious effort to confront the disease head-on. Now in its second phase, TAAP-2 represents a significant evolution in both scientific scope and clinical ambition. More

This article is based on materials from the “Translational Asian Age-related Macular Degeneration Programme Phase 2 (TAAP-2)” Open Fund Large Collaborative Grant Factsheet and related programme documents from the Singapore Eye Research Institute and collaborating institutions.

Funding for this research programme was provided by the Singapore Ministry of Health’s National Medical Research Council under its Open-Fund Large Collaborative Grant (Project number: OFLCG23may-0032).

For further information, please contact Professor Gemmy Cheung at gemmy.cheung.c.m@singhealth.com.sg

This work is licensed under a Creative Commons Attribution 4.0 International License. 

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.